Aligning Standards and Innovation in Bioprinting
Brinter AM Technologies is proud to announce a strategic collaboration with Regsmart and Uppsala University to develop an open-source framework for the 3MF bio file format. This project will integrate material metadata, emerging ISO standards, and automated regulatory compliance checks—creating a robust foundation for next-generation bioprinting workflows.
Project Overview
- Title:
Open-source framework for the 3MF bio file format, integrating material attributes, ISO standards, and regulatory compliance for bioprinting - Partners:
- Brinter AM Technologies
- Uppsala University
- Regsmart
Why This Matters for the AM Field
- Interoperability Across Platforms
By building on the 3MF bio format—an open, XML-based file standard—the framework ensures that design files, material properties, and process parameters can flow seamlessly between printers, slicers, and analysis tools. This breaks down vendor lock-in and accelerates collaborative research. - Embedded Regulatory Intelligence
Integrating Regulatory compliance engine directly into the file format allows users to flag potential regulatory issues (e.g., material biocompatibility, traceability requirements) at the design stage. Early detection reduces costly rework and speeds time-to-clinic. - Alignment with ISO Standards
Our partnership with Uppsala University will map the latest ISO 52900-series (Additive Manufacturing) and ISO 10993 (Biological evaluation of medical devices) requirements to the 3MF bio schema. This makes it easier for device manufacturers and research teams to meet international quality benchmarks. - Community-Driven, Open-Source Development
An open-license GitHub repository (coming Q3 2025) invites the global AM community to contribute extensions—whether new material libraries, custom compliance modules, or advanced metadata schemes—fostering rapid innovation and shared best practices.
Shaping the Future of Additive Manufacturing
This project represents a major step toward standardized, transparent, and compliant bioprinting processes. By embedding material data, regulatory rules, and ISO alignment into a single, open file format, we’re enabling:
- Faster R&D cycles through plug-and-play data exchange
- Greater confidence for clinicians and regulators in bioprinted products
- Scalable collaborations across academia, startups, and major equipment suppliers
At Brinter AM Technologies, we believe that open standards underpin sustainable growth in the life-science 3D printing ecosystem—laying the groundwork for breakthroughs in tissue engineering, implantable devices, and personalized medicine.
The Brinter AM Technologies Commitment
At Brinter AM Technologies, our passion for advanced manufacturing and biomedical innovation drives us to constantly push the boundaries of what is possible. Our role in AM4Life is defined by our commitment to:
- Leveraging Advanced 3D Printing Solutions: Utilizing our state-of-the-art printing platforms and expertise to contribute to the development of next-generation bioactive materials and devices.
- Innovative Research and Development: Pioneering efforts in the field of high-resolution and multi-material printing, we are focused on overcoming the technical challenges that impede the creation of reliable, scalable healthcare solutions.
- Collaboration and Knowledge Sharing: Working closely with academic and healthcare partners, we aim to ensure that innovations are seamlessly translated from the lab to clinical practice. This collaboration is at the heart of accelerating research breakthroughs and enhancing patient care.
Our active participation in AM4Life allows us to apply our unique capabilities in additive manufacturing to create tangible impacts in regenerative medicine and personalized healthcare.
A Collaborative Platform Backed by VINNOVA
The AM4Life consortium is powered by VINNOVA, Sweden’s Innovation Agency, and represents a forward-thinking approach to healthcare innovation. With a funding model that equally supports academia, industry, and public sector initiatives, the consortium is uniquely positioned to deliver groundbreaking results over its 10-year timeline (2020–2029). As AM4Life enters its second phase (2025–2029), it brings together an even broader network of partners—23 industrial, 9 academic, and 3 public organisations—ensuring a diverse and dynamic approach to tackling today’s healthcare challenges.
Looking Ahead: Phase 2 Ambitions
In the upcoming phase of AM4Life, the focus will be on scaling up innovations and deepening collaborative efforts. The goals are ambitious: from significantly increasing the number of scientific publications and patent applications to developing a range of new products and processes that enhance patient care. We at Brinter AM Technologies are excited to be at the forefront of this evolution, driving forward research that brings us closer to making personalized, 3D-printed medical solutions a clinical reality.
Join Us on the Journey
We invite you to follow Brinter AM Technologies and the AM4Life consortium as we work together to revolutionize healthcare through additive manufacturing. Stay connected for updates on our progress, breakthrough research, and opportunities to collaborate in transforming life sciences.
Together, let’s build the future of healthcare—one innovative layer at a time!
For further updates, follow our page on LinkedIn
